Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Surgical Pathology ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms.Leukemia. 2022; 36: 1720-1748
- Next-generation sequencing discoveries in lymphoma.Adv Anat Pathol. 2013; 20: 110-116
- Genetic profiling and biomarkers in peripheral T-cell lymphomas: current role in the diagnostic work-up.Mod Pathol. 2022; 35: 306-318
- Genetic landscape and deregulated pathways in B-cell lymphoid malignancies.J Intern Med. 2017; 282: 371-394
- MYD88 L265P somatic mutation in Waldenström's macroglobulinemia.N Engl J Med. 2012; 367: 826-833
- MYD88 L265P mutation in Waldenstrom macroglobulinemia.Blood. 2013; 121: 4504-4511
- MYD88 L265P mutation analysis helps define nodal lymphoplasmacytic lymphoma.Mod Pathol. 2015; 28: 564-574
- The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis.Blood. 2014; 123: 1637-1646
- Clinical and molecular characteristics of lymphoplasmacytic lymphoma not associated with an IgM monoclonal protein: A multicentric study of the Rete Ematologica Lombarda (REL) network.Am J Hematol. 2019; 94: 1193-1199
- MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenström's macroglobulinemia.Leukemia. 2013; 27: 1722-1728
- Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment Strategies.J Clin Oncol. 2020; 38: 1198-1208
- Insights into the genomic landscape of MYD88 wild-type Waldenström macroglobulinemia.Blood Adv. 2018; 2: 2937-2946
- Molecular and genetic biomarkers implemented from next-generation sequencing provide treatment insights in clinical practice for Waldenström macroglobulinemia.Neoplasia. 2021; 23: 361-374
- Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib.N Engl J Med. 2014; 370: 2286-2294
- Diagnostic Next-generation Sequencing Frequently Fails to Detect MYD88(L265P) in Waldenström Macroglobulinemia.Hemasphere. 2021; 5: e624
- Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma.Nat Genet. 2014; 46: 176-181
- Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin.Nat Genet. 2010; 42: 181-185
- Inactivating mutations of acetyltransferase genes in B-cell lymphoma.Nature. 2011; 471: 189-195
- EZH2 mutations are frequent and represent an early event in follicular lymphoma.Blood. 2013; 122: 3165-3168
- Mutations in linker histone genes HIST1H1 B, C, D, and E; OCT2 (POU2F2); IRF8; and ARID1A underlying the pathogenesis of follicular lymphoma.Blood. 2014; 123: 1487-1498
- From genetics to the clinic: a translational perspective on follicular lymphoma.Nat Rev Cancer. 2018; 18: 224-239
- Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry.Lancet Oncol. 2015; 16: 1111-1122
- Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy.Blood. 2016; 128: 1112-1120
- Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial.Lancet Oncol. 2020; 21: 1433-1442
- Tazemetostat: EZH2 Inhibitor.J Adv Pract Oncol. 2022; 13: 158-163
- Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma.Blood. 2012; 119: 1963-1971
- Landscape of somatic mutations and clonal evolution in mantle cell lymphoma.Proc Natl Acad Sci U S A. 2013; 110: 18250-18255
- The E3 ubiquitin ligase UBR5 is recurrently mutated in mantle cell lymphoma.Blood. 2013; 121: 3161-3164
- The genomic landscape of mantle cell lymphoma is related to the epigenetically determined chromatin state of normal B cells.Blood. May 8 2014; 123: 2988-2996
- TP53 mutations are common in mantle cell lymphoma, including the indolent leukemic non-nodal variant.Ann Diagn Pathol. 2019; 41: 38-42
- Genetic mutations and features of mantle cell lymphoma: a systematic review and meta-analysis.Blood Adv. 2020; 4: 2927-2938
- Coding and noncoding drivers of mantle cell lymphoma identified through exome and genome sequencing.Blood. 2020; 136: 572-584
- TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy.Blood. 2017; 130: 1903-1910
- Mantle cell lymphoma - advances in molecular biology, prognostication and treatment approaches.Br J Haematol. Oct 2021; 195: 162-173
- High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma.Blood. 2015; 126: 604-611
- Pharmacological and genomic profiling identifies NF-κB-targeted treatment strategies for mantle cell lymphoma.Nat Med. 2014; 20: 87-92
- Genetic heterogeneity in primary and relapsed mantle cell lymphomas: Impact of recurrent CARD11 mutations.Oncotarget. Jun 21 2016; 7: 38180-38190
- CCND1 mutations increase protein stability and promote ibrutinib resistance in mantle cell lymphoma.Oncotarget. 2016; 7: 73558-73572
- The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma.N Engl J Med. 2002; 346: 1937-1947
- Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray.Blood. 2004; 103: 275-282
- Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma.Nature. Jun 4 2009; 459: 717-721
- Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma.Nature. Jul 27 2011; 476: 298-303
- Analysis of the coding genome of diffuse large B-cell lymphoma.Nat Genet. 2011; 43: 830-837
- The genetic landscape of diffuse large B-cell lymphoma.Semin Hematol. 2015; 52: 67-76
- Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma.N Engl J Med. 2018; 378: 1396-1407
- Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes.Nat Med. 2018; 24: 679-690
- Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report.Blood. 2020; 135: 1759-1771
- A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications.Cancer Cell. 2020; 37: 551-568.e14
- Molecular profiling in diffuse large B-cell lymphoma: why so many types of subtypes?.Br J Haematol. 2022; 196: 814-829
- Oncogenically active MYD88 mutations in human lymphoma.Nature. 2011; 470: 115-119
- Targetable activating mutations are very frequent in GCB and ABC diffuse large B-cell lymphoma..Genes Chromosomes Cancer. 2014; 53: 144-153
- Analysis of FOXO1 mutations in diffuse large B-cell lymphoma.Blood. 2013; 121: 3666-3674
- Targeting pathological B cell receptor signalling in lymphoid malignancies.Nat Rev Drug Discov. 2013; 12: 229-243
- Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma.Cancer Cell. Apr 13 2015; 27: 516-532
- STAT3 and TP53 mutations associate with poor prognosis in anaplastic large cell lymphoma.Leukemia. 2021; 35: 1500-1505
- Recurrent MSC (E116K) mutations in ALK-negative anaplastic large cell lymphoma.Blood. 2019; 133: 2776-2789
- ALK kinase domain mutations in primary anaplastic large cell lymphoma: consequences on NPM-ALK activity and sensitivity to tyrosine kinase inhibitors.PLoS One. 2015; 10: e0121378
- Whole Exome Sequencing reveals NOTCH1 mutations in anaplastic large cell lymphoma and points to Notch both as a key pathway and a potential therapeutic target.Haematologica. Jun 1 2021; 106: 1693-1704
- Activating mutations in genes related to TCR signaling in angioimmunoblastic and other follicular helper T-cell-derived lymphomas.Blood. 2016; 128: 1490-1502
- Integrative clinicopathological and molecular analyses of angioimmunoblastic T-cell lymphoma and other nodal lymphomas of follicular helper T-cell origin.Haematologica. 2017; 102: e148-e151
- The pathological features of angioimmunoblastic T-cell lymphomas with IDH2(R172) mutations.Mod Pathol. 2019; 32: 1123-1134
- Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma.Blood. 2019; 133: 1664-1676
- The Future of Combination Therapies for Peripheral T Cell Lymphoma (PTCL).Curr Hematol Malig Rep. 2018; 13: 13-24
- T follicular helper phenotype predicts response to histone deacetylase inhibitors in relapsed/refractory peripheral T-cell lymphoma.Blood Adv. 2020; 4: 4640-4647
- Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma.Blood. 2014; 123: 2915-2923
- Reproducing the molecular subclassification of peripheral T-cell lymphoma-NOS by immunohistochemistry.Blood. 2019; 134: 2159-2170
- Molecular heterogeneity in peripheral T-cell lymphoma, not otherwise specified revealed by comprehensive genetic profiling.Leukemia. 2019; 33: 2867-2883
- Whole exome sequencing reveals mutations in FAT1 tumor suppressor gene clinically impacting on peripheral T-cell lymphoma not otherwise specified.Mod Pathol. 2020; 33: 179-187
Article info
Publication history
Published online: March 15, 2023
Publication stage
In Press Corrected ProofIdentification
Copyright
© 2023 Elsevier Inc. All rights reserved.
